AIM: To determine the association between sarcopenia and prognosis in patients with metastatic gastric cancer (mGC) receiving chemotherapy. PATIENTS AND METHODS: Our study retrospectively evaluated 231 consecutive Japanese patients with mGC who commenced first-line chemotherapy at our Institution between January 2013 and December 2015. Muscle loss during chemotherapy was defined as a ≥10% reduction in the skeletal muscle index and was evaluated for its association with time to treatment failure (TTF) and overall survival (OS). RESULTS: Of 118 patients, 89% had baseline sarcopenia and 31% developed muscle loss. Muscle loss was significantly associated with shorter TTF and OS and was an independent prognostic factor for both these parameters; poor performance status and poorer differentiation on histology were also significant predictors of shorter OS. However, muscle loss was not significantly associated with increased grade 3 or higher toxicities. CONCLUSION: Muscle loss during chemotherapy negatively affected survival among patients with mGC. Copyright
AIM: To determine the association between sarcopenia and prognosis in patients with metastatic gastric cancer (mGC) receiving chemotherapy. PATIENTS AND METHODS: Our study retrospectively evaluated 231 consecutive Japanese patients with mGC who commenced first-line chemotherapy at our Institution between January 2013 and December 2015. Muscle loss during chemotherapy was defined as a ≥10% reduction in the skeletal muscle index and was evaluated for its association with time to treatment failure (TTF) and overall survival (OS). RESULTS: Of 118 patients, 89% had baseline sarcopenia and 31% developed muscle loss. Muscle loss was significantly associated with shorter TTF and OS and was an independent prognostic factor for both these parameters; poor performance status and poorer differentiation on histology were also significant predictors of shorter OS. However, muscle loss was not significantly associated with increased grade 3 or higher toxicities. CONCLUSION:Muscle loss during chemotherapy negatively affected survival among patients with mGC. Copyright
Authors: Stefano Rotolo; Andrea Di Giorgio; Marco Cintoni; Emanuele Rinninella; Marta Palombaro; Gabriele Pulcini; Carlo Alberto Schena; Vito Chiantera; Giuseppe Vizzielli; Antonio Gasbarrini; Fabio Pacelli; Maria Cristina Mele Journal: Pleura Peritoneum Date: 2022-03-01
Authors: Song Ee Park; Jin Hwa Choi; Jae Yong Park; Beom Jin Kim; Jae Gyu Kim; Jong Won Kim; Joong-Min Park; Kyong-Choun Chi; In Gyu Hwang Journal: Sci Rep Date: 2020-10-19 Impact factor: 4.379
Authors: Laura F J Huiskamp; Najiba Chargi; Lot A Devriese; Anne M May; Alwin D R Huitema; Remco de Bree Journal: J Clin Med Date: 2020-11-23 Impact factor: 4.241
Authors: Lucy X Ma; Kirsty Taylor; Osvaldo Espin-Garcia; Reut Anconina; Chihiro Suzuki; Michael J Allen; Marta Honorio; Yvonne Bach; Frances Allison; Eric X Chen; Savtaj Brar; Carol J Swallow; Jonathan Yeung; Gail E Darling; Rebecca Wong; Sangeetha N Kalimuthu; Raymond W Jang; Patrick Veit-Haibach; Elena Elimova Journal: Cancer Med Date: 2020-12-09 Impact factor: 4.452
Authors: Marine Perrier; Marie-Amelie Ordan; Coralie Barbe; Camille Mazza; Damien Botsen; Johanna Moreau; Yohann Renard; Mathilde Brasseur; Barbara Tailliere; Philippe Regnault; Eric Bertin; Olivier Bouche Journal: Support Care Cancer Date: 2021-07-12 Impact factor: 3.603